Business Wire

TX-MARY-KAY

15.9.2022 17:06:38 CEST | Business Wire | Press release

Share
Mary Kay Challenges Global Youth to Address SDG 14: Life Below Water in Third Annual Network for Teaching Entrepreneurship World Series of Innovation Challenge

Mary Kay Inc., a leading corporate advocate of women’s empowerment and entrepreneurship, announces its third annual World Series of Innovation (WSI) challenge in partnership with Network for Teaching Entrepreneurship (NFTE). The global competition invites young people ages 13-24 to put their critical thinking skills to the test and get involved in solving some of the biggest challenges humanity faces today to advance the UN Sustainable Development Goals (SDGs).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005847/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Network for Teaching Entrepreneurship an international nonprofit organization providing entrepreneurship training and educational programs to middle and high school students, college students, and adults (Graphic: Network for Teaching Entrepreneurship)

Mary Kay’s WSI challenge kicks off September 15 in conjunction with World Clean Up Day. The Mary Kay challenge encourages young entrepreneurs to submit innovative solutions to address UN SDG 14: Life Below Water. Specifically, students are challenged to design a solution to further the conservation and/or protection of the world’s marine ecosystems and coastal communities.

“All life on Earth began in and depends on our oceans. Water is the most valuable resource on our planet, and it’s essential that we not only respect it, but do our part to protect it,” said Deborah Gibbins, Chief Operating Officer for Mary Kay Inc. “The next generation of global thinkers and leaders are already addressing these critical areas of concern and spearheading conservation efforts. We are excited to see how the world’s youth can help to advance ecosystems and biodiversity conservation globally.”

In its first year partnering with the NFTE World Series of Innovation in 2020, Mary Kay sponsored a WSI challenge for UN SDG 12: Responsible Consumption and Production. Young entrepreneurs were encouraged to design a product, service or initiative that promoted the reuse or upcycling of textiles. In 2021, Mary Kay sponsored its second WSI challenge to address UN SDG 5: Gender Equality. Students were tasked with developing programs to promote workplace equality and ensure equal access to economic opportunity for women and girls.

“Mary Kay Global Oceans Conservations Challenge dares our young WSI competitors to think big about water quality,” said Dr. J.D. LaRock, President and CEO of NFTE. “In classrooms, students learn that water is fundamental to a healthy ecosystem. Through experiences like WSI, however, they become empowered to sustain that resource. They can ideate ways to look after marine life, safeguard oceans, secure affordable access to clean drinking water, protect water resources from pollution, address overconsumption, or otherwise help preserve our ecosystem for generations to come. That’s powerful.”

NFTE is a global educational non-profit focused on bringing the power of entrepreneurship to low-income communities. Since its founding more than 35 years ago, NFTE has trained thousands of teachers and educated well over a million young people worldwide. Every fall, NFTE launches a new set of challenges for the WSI competition and invites corporate sponsors to address the UN SDGs. The 2022 NFTE World Series of Innovation is presented by Citi Foundation and features challenges sponsored by Mary Kay Inc., MetLife Foundation, Mastercard, Bank of the West, Link, Maxar, Ernst & Young, LLP (EY), ServiceNow and Zuora. The top three winners will be announced in early 2023.

For more information on the World Series of Innovation and all challenges, visit https://innovation.nfte.com/.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005847/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye